BERGER FRANKLIN M

Average Profitability
<0.0001%
Insider Buys Quantity
9
Insider Buys Sum
$4.76M
Insider Sells Quantity
5
Insider Sells Sum
$729,051.78

Insider Activity of BERGER FRANKLIN M

According to the SEC Form 4 filings, BERGER FRANKLIN M, being in a position of

  1. director at ESSA Pharma Inc.,
    оver the last 12 months, has bought 23259 shares for $133,274, and sold 0 shares,
    over all time since 2021-02-22, has bought 156730 shares for $2.09M, and sold 272840 shares for $729,052.

The largest purchase of all time was on 2021-02-22 and amounted to 57000 shares of ESSA Pharma Inc. for $1.54M.

The largest sale of all time was on 2022-12-15 and amounted to 82000 shares of ESSA Pharma Inc. for $235,800.

Biography of BERGER FRANKLIN M

No biography is available at this moment.

2023-11-21PurchaseESSA Pharma Inc.
EPIX
director
23,259
0.0523%
$5.73$133,274+7.4%
2023-11-03PurchaseESSA Pharma Inc.
EPIX
director
16,471
0.0373%
$5.99$98,661+3.83%
2023-11-02PurchaseESSA Pharma Inc.
EPIX
director
60,000
0.1371%
$5.35$321,000+16.45%
2022-12-21SaleESSA Pharma Inc.
EPIX
director
72,223
0.1656%
$2.41$174,401+23.01%
2022-12-20SaleESSA Pharma Inc.
EPIX
director
43,617
0.0986%
$2.53$110,351+15.75%
2022-12-16SaleESSA Pharma Inc.
EPIX
director
50,000
0.1156%
$2.67$133,500+12.21%
2022-12-15SaleESSA Pharma Inc.
EPIX
director
82,000
0.1884%
$2.88$235,800+3.52%
2022-12-14SaleESSA Pharma Inc.
EPIX
director
25,000
0.0569%
$3.00$75,000-1.67%
2022-03-18PurchaseKezar Life Sciences, Inc.
KZR
20,000
0.0313%
$14.77$295,400-52.05%
2021-02-22PurchaseESSA Pharma Inc.
EPIX
director
57,000
0.1573%
$27.00$1.54M-48.45%
2020-06-11PurchaseKezar Life Sciences, Inc.
KZR
director
100,000
0.2647%
$5.50$550,000+13.64%
2020-02-04PurchaseKezar Life Sciences, Inc.
KZR
director
120,846
0.3145%
$2.60$314,200+69.08%
2018-06-25PurchaseKezar Life Sciences, Inc.
KZR
director
100,000
4.279%
$15.00$1.5M+15.16%
2013-08-20PurchaseLineage Cell Therapeutics, Inc.
LCTX
director
1,000
0.0018%
$3.71$3,709-5.78%
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.